Molecular Medicine Reports Molecular Medicine Reports 1791-2997 1791-3004 D.A. Spandidos 10.3892/mmr.2018.9499 mmr-18-06-4904 Articles A family with hypothyroidism caused by fatty acid synthase and apolipoprotein B receptor mutations SunJianhua 1 SunLizhi 2 ChenWeijie 3 YinXiao 3 LuYong 3 JiangQiang 3 Department of Oncology, The Second Hospital of Shandong University, Jinan, Shandong 250033, P.R. China Central Laboratory, Jinan Central Hospital Affiliated to Shandong University, Jinan, Shandong 250013, P.R. China Department of Endocrinology, Jinan Central Hospital Affiliated to Shandong University, Jinan, Shandong 250013, P.R. China Correspondence to: Dr Qiang Jiang, Department of Endocrinology, Jinan Central Hospital Affiliated to Shandong University, 105 Jiefang Road, Jinan, Shandong 250013, P.R. China, E-mail: jiangqiangjinan@sina.com 122018 20092018 18 6 4904 4912 02022018 15082018 Copyright: © Sun et al. 2018 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Hypothyroidism is a disease with a genetic component. The present study aimed to identify the potential causative gene mutation in a family with hypothyroidism and to investigate its potential pathology. DNA was extracted from the affected individual and his parents, maternal aunt and maternal grandmother. Whole exome sequencing was used to examine their exomes. The potential causative genes that may have an autosomal dominant mode of inheritance were selected after variant calling and filtering. Bioinformatics analysis was utilized to predict the deleteriousness of the identified variants, and multiple sequence alignment and conserved protein domain analyses were performed using online software. Finally, Sanger sequencing was used to validate the identified variants. In the present study, a total of 50 variants were screened based on the autosomal dominant mode of inheritance. Two variants, the fatty acid synthase (FASN) and apolipoprotein B receptor (APOBR) genes, were further analyzed, as they were highly associated with hypothyroidism. Genotyping results revealed that two mutations, c.G7192T (p.A2398S) in the FASN gene and c.C1883G (p.T628R) in the APOBR gene, were fully co-segregated with established hypothyroidism phenotypes in the family. These mutations were located in the conserved α/β-hydrolase fold and Na+/Ca2+ exchanger superfamily domain of FASN and APOBR, respectively. In conclusion, the present study demonstrated that the FASN c.G7192T and APOBR c.C1883G mutations may be the potential causative variants in this Chinese hypothyroidism pedigree.

 WES hypothyroidism FASN APOBR Introduction

Thyroid hormones (triiodothyronine and thyroxine) are major regulators of diverse metabolic pathways via interactions with thyroid hormone nuclear receptors in various tissues (1–3). Maintaining thyroid hormone levels is essential for development and metabolism. Hypothyroidism, one of several thyroid diseases, is a pathological state where thyroid hormone levels are decreased systemically or locally in one or more tissues. The prevalence of hypothyroidism is sizeable and ranges between 3–18% in the adult population, with women, elderly persons and populations with iodine deficiency or excess being more often affected (4,5). Generally, hypothyroidism is diagnosed either in the subclinical or clinical form. Congenital hypothyroidism, if not treated, may lead to severe and irreversible mental retardation (6).

Hypothyroidism is associated with various symptoms, including cold sensitivity, fatigue and lethargy, cognitive dysfunction and delayed growth; these symptoms can be accompanied by distinct signs of tachycardia, weight loss and attention deficit-hyperactivity disorder (7,8). Two of the main characteristics of hypothyroidism are the marked impairment of lipid metabolism and dyslipidemia (9,10). Furthermore, hypercholesterolemia induces increased concentrations of total and low-density lipoprotein cholesterol (11), which will affect normal metabolism. At present, the genetic mechanism implicated in the pathogenesis of hypothyroidism remains poorly understood. It has been reported that mutations in the NK2 homeobox 1 and forkhead box E1 (FOXE1) genes cause hypothyroidism (12,13). In addition, a mutation in immunoglobulin superfamily member 1 has been revealed to be associated with central hypothyroidism (X-linked syndrome) (14). Loss-of-function mutations in thyroglobulin, paired box 8, thyroid-stimulating hormone receptor, FOXE1, NK2 homeobox (NKX2)-1 and NKX2-5 genes are also associated with inherited congenital hypothyroidism (15,16). Therefore, identifying candidate gene mutations may be helpful in understanding the pathology of hypothyroidism.

Whole exome sequencing (WES) is a useful tool for exploring the genetic mechanism of different diseases (17–19). The present study investigated a Chinese hypothyroidism pedigree, which included an affected proband, mother and maternal grandmother; other relatives were unaffected. The results indicated that the c.G7192T (p.A2398S) mutation in fatty acid synthase (FASN) and the c.C1883G (p.T628R) mutation in apolipoprotein B receptor (APOBR) may be the most likely causes of the disease. These results on the inheritance of mutant genes may provide novel information regarding the pathological mechanism underlying hypothyroidism.

 Materials and methods <sec> <title>Subjects and family members

The present study examined a three-generation hypothyroidism pedigree residing in China. The proband (IV:1) was a 3.9-year-old boy who was diagnosed with hypothyroidism. Furthermore, his mother (III:2) and maternal grandmother (II:3) also had hypothyroidism, and all of them shared common characteristics (Fig. 1). In addition, family members I:1 and II:1 were diagnosed with subclinical hypothyroidism, and II:5 was a probable case. The father, maternal aunt and paternal grandparents of the proband were unaffected. Therefore, it was hypothesized that the etiology of hypothyroidism in this family had an autosomal dominant mode of inheritance. Therefore, the proband, along with his parents, maternal aunt and maternal grandmother were enrolled for whole exome sequencing (Fig. 1). Written informed consent was obtained from all individuals enrolled in this study. In addition, the present study was approved by the ethical approval committee of Jinan Central Hospital Affiliated to Shandong University (2016-053-01; Jinan, China).

 Exome sequencing and variant calling

Venous blood was obtained from the affected individuals (IV:1, III:2 and II:3) and two unaffected individuals (III:1 and III3) in the hypothyroidism pedigree. The collected blood was stored in EDTA, followed by DNA extraction using a kit (Tiangen Biotech Co., Ltd., Beijing, China). The Agilent SureSelect Human All Exon 50Mb Exon kit (Agilent Technologies, Inc., Santa Clara, CA, USA) was used to perform exome target enrichment of quantified genomic DNA. The amplification process was performed under the following conditions: 15 min at 95°C followed by 40 cycles of 10 sec at 95°C, 30 sec at 55°C, 32 sec at 72°C, and 15 sec at 95°C, 60 sec at 60°C, 15 sec extension at 95°C. The Illumina HiSeq 4000 Sequencer (Illumina, San Diego, CA, USA) was utilized for WES. Sequencing reads that had paired-ends, were 200-bp long and had a mean coverage of 100× were generated for each sample. After filtering out adapter sequences, and contaminated and low quality reads, the clean paired reads were then mapped to the reference human genome sequence, hg19 (20), using the Burrows-Wheeler alignment tool, generating the sequence alignment/map file. Picard software program (version 1.07) was used to mark and remove polymerase chain reaction (PCR) duplicate reads. MuTect (version 1.1.4) and Genome Analysis Toolkit software (version 3.1) (21,22) were used to identify single nucleotide variants (SNVs), deletions and insertions throughout the genome.

 Variant filtering

To identify potential candidate genes, the variants were annotated in a systematic manner. Variant information was annotated using various genetic variation databases by the program ANNOVAR (23). From the reported variant frequencies, variants with a minor allele frequency >0.01 in the 1000 Genomes Project (https://www.nature.com/articles/nature15393) were excluded. Based on the variant location within genes, higher priority was given to the variants in the coding region and variants that altered the coding sequence (nonsynonymous variants) were identified. The deleteriousness of identified variants was then predicted by bioinformatics analysis [e.g. Oncotator v1.5.3.0, sift (http://sift.jcvi.org/) and polyphen (http://genetics.bwh.harvard.edu/pph2/)], and the harmful nonsynonymous variants were obtained. The eligible nonsynonymous variants were identified using the following filtering parameter criteria in the Genome Analysis Toolkit software (v3.1) (https://software.broadinstitute.org/gatk/): QualByDepth>2.0, FisherStrand<60.0, StrandOddsRatio<4.0, RMSMappingQuality (MQ)>40.0, MQRankSumTest>-12.5, ReadPosRankSumTest>-8.0. In addition, minor allele frequency <0.05 was also included.

 In silico analysis

The multiple sequence alignment of FASN and APOBR in different species was performed using an online tool (https://www.ncbi.nlm.nih.gov/tools/cobalt/cobalt.cgi?LINK_LOC=BlastHomeLink). In addition, the Conserved Domain Search Service (http://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi) was used to identify the conserved protein domains.

 Sanger sequencing

After the systematic filtering, two candidate variants (FASN c.G7192T, p.A2398S and APOBR c.C1883G, p.T628R) were confirmed. Genomic DNA was prepared from the proband, ten family members and twenty additional, unrelated, affected individuals. Primer-Premier 5.0 (Premier Biosoft International, Palo Alto, CA, USA) was used to design oligonucleotide primer sets for the variants. PCR analyses and Sanger sequencing were then performed. The amplification process was: 15 min at 95°C followed by 40 cycles of 10 sec at 95°C, 30 sec at 55°C, 32 sec at 72°C, and 15 sec at 95°C, 60 sec at 60°C, 15 sec extension at 95°C. The PCR products were used for Sanger sequencing.

 Results <sec> <title>Genetic and in silico analysis

Genomic DNA samples from IV:1, III:1, III:2, III:3 and II:3 were analyzed. A total of 50 nonsynonymous variants were identified (Table I). Based on the hypothyroidism in the pedigree and subsequent Sanger sequencing results (Table II), two SNVs, the c.G7192T mutation (a substitution from C to A) in FASN (Chr17: 80037439) and the c.C1883G mutation (a substitution from C to G) in APOBR (Chr16: 28508245), were likely to be associated with the disease. In pedigree individuals, the results of II:3, II:5, III:2 and IV:1 showed the c.G7192T mutation in FASN (Chr17: 80037439) and the c.C1883G mutation in APOBR.

 In silico analysis

The c.G7192T mutation in FASN resulted in a protein alteration of p.A2398S. In addition, the c.C1883G mutation in APOBR resulted in a protein alteration of p.T628R. Furthermore, multiple sequence alignment and conserved protein domain analyses indicated that the amino acid at position 2,398 in the FASN protein sequence was located in the α/β-hydrolase fold, and it was highly conserved across several species, including humans, rats, chimpanzees, monkeys, cows and goats (Fig. 2). Furthermore, the amino acid at position 628 in the APOBR protein sequence was located in the Na+/Ca2+ exchanger superfamily, and it was highly conserved across several species, including humans, monkeys, camels, chimpanzees, pigs and rats (Fig. 3).

 Sanger sequencing of the candidate causative variants

In order to further confirm the c.G7192T and c.C1883G mutations in hypothyroidism, Sanger sequencing was performed on the 11 family members and on 20 additional, unrelated individuals with primary hypothyroidism. The clinical information of the 20 additional, unrelated individuals with primary hypothyroidism is presented in Table III. The results demonstrated that the c.G7192T mutation in FASN and the c.C1883G mutation in APOBR were fully co-segregated with established hypothyroidism phenotypes in the family recruited for WES (Figs. 4 and 5). Furthermore, the FASN c.G7192T and APOBR c.C1883G mutations were detected in the patient with probable hypothyroidism (II:5). It is worth mentioning that the FASN c.G7192T and APOBR c.C1883G mutations were not observed in individuals with subclinical hypothyroidism (I:1, II:1). In addition, the mutations were not detected in the unrelated, affected individuals with hypothyroidism (date not shown), which supported the hypothesis of genetic heterogeneity of hypothyroidism in this family.

 Discussion

Hypothyroidism is the most common endocrine disorder caused by thyroid hormone deficiency, which can induce metabolic dysfunction (24). At present, the genetic mechanisms underlying hypothyroidism pathogenesis remain poorly understood. It has been reported that the c.1184_1187dup4 mutation in the thyroid peroxidase gene, c.40A>G and c.94G>A mutations in the thyroid-stimulating hormone β gene, p.G488R, p.A649E, p.R885Q, p.I1080T and p.A1206T mutations in the dual oxidase 2 gene, and the p.Y138X mutation in the dual oxidase maturation factor 2 gene are associated with congenital hypothyroidism (25–27). WES technology is an effective method for identifying potential causative genes in disease phenotypes. In the present study, WES was performed to identify potential causative genes in the affected individual, his parents, maternal aunt and maternal grandmother in a hypothyroidism pedigree. Two mutations (c.G7192TT and c.C1883G) in the FASN and APOBR genes, respectively, were revealed to be associated with hypothyroidism. In addition, Sanger sequencing validated these FASN and APOBR mutations in the proband and his mother. Furthermore, the mutations were fully co-segregated with established hypothyroidism phenotypes in the family.

Fatty acid synthesis is a process that entails producing de novo fatty acids from carbohydrate- and amino acid-derived carbon sources. The liver serves a key role in fatty acid modulation. The key enzymes in the lipogenic and lipolytic pathways are regulated by thyroid hormones in the liver and adipose tissues (28,29). Disrupted thyroid hormone levels alter hepatic fatty acid composition (30). In addition, it has been reported that subclinical and clinical hypothyroidism are associated with hepatic steatosis (31). Numerous studies have indicated that hypothyroidism is a risk factor for nonalcoholic fatty liver disease and results in metabolic syndrome (32–34). In addition, the effects of hypothyroidism to enhance lipogenesis is amplified in the presence of physiological concentrations of fatty acids (35). FASN is an enzyme involved in fatty acid biosynthesis (36). In mammals, cells manufacture de novo fatty acids using different pathways, which synthesize fatty acids from acetyl and malonyl esters of CoA that are catalyzed by dimerized FASN (37). Furthermore, fatty acid synthesis is controlled by FASN (38), and the downregulation of FASN protein levels causes markedly decreased regulation of de novo lipogenesis (30). Notably, FASN is downregulated in the livers of patients with hypothyroidism (39). In addition, a microarray analysis revealed that FASN, one of the hepatic target genes, is preferentially activated by triiodothyronine during transition from the hypothyroid state to the euthyroid state (40). The c.G7192T mutation is located in the conserved α/β-hydrolase fold of FASN and was highly conversed among several diverse species, including humans, rats, chimpanzees, monkeys, cows and goats. Therefore, this FASN mutation suggested that FASN may have roles in hypothyroidism.

APOBR is an apolipoprotein E-independent receptor that binds APOB48, allowing cells to uptake postprandial triglyceride-rich lipoproteins, for which APOBR has a high affinity; APOBR functions as a nutritional receptor that provides dietary fatty acids and lipid-soluble vitamins to cells (41). The APOBR protein is distributed in the moieties of plasma triglyceride-rich lipoproteins. It has been reported that APOBR is an important molecule in lipid metabolism, and that it primarily serves roles in the sterol transport and metabolism pathways (42). Mutations in the APOBR gene (c.934-960/del and A419P) have been identified as novel hyperlipidemia-associated variants, which may be involved in regulating plasma total cholesterol levels in patients with hypercholesterolemia (43). APOBR is also involved in atherogenesis, which is a lipid metabolism disorder (44). Therefore, it may be hypothesized that the APOBR pathway is a novel therapeutic target, particularly in hypertriglyceridemic patients, such as those with hypothyroidism. In the present study, a mutation (c.C1883G, p.T628R) in the APOBR gene was detected in patients with hypothyroidism. The mutation is located in the conserved Na+/Ca2+ exchanger domain of APOBR and was highly conversed among different species, including humans, monkeys, camels, chimpanzees, pigs and rats. Therefore, this APOBR mutation may be considered another candidate molecule in the pathogenesis of hypothyroidism.

In conclusion, the findings reported here demonstrated that patients with mutations in FASN (c.G7192T, p.A2398S) and APOBR (c.C1883G, p.T628R) may be predisposed to hypothyroidism. These mutations may disrupt the regulation of fatty acid biosynthesis and lipid metabolism. These findings may reveal the high degree of genetic heterogeneity in hypothyroidism phenotypes. Future work will be performed to improve understanding of this disorder. In addition, there is a limitation of the present study; the identified SNVs, FASN (c.G7192T, p.A2398S) and APOBR (c.C1883G, p.T628R), require validation in animal models of hypothyroidism.

 Acknowledgements

Not applicable.

 Funding

Not applicable.

 Availability of data and materials

All data generate or analyzed during the present study are included in this published article.

 Authors' contributions

JS, LS, WC, XY and YL analyzed and interpreted the data. JS was a major contributor in writing the manuscript. QJ designed the project. All authors read and approved the final manuscript.

 Ethics approval and consent to participate

Written informed consent was obtained from all individuals enrolled in this study. In addition, the present study was approved by the ethical approval committee of Jinan Central Hospital Affiliated to Shandong University (2016-053-01).

 Patient consent for publication

Informed written consent was obtained from all subjects.

 Competing interests

The authors declare that they have no competing interests.

 Abbreviations APOBR

apolipoprotein B receptor

 FASN

fatty acid synthase

 SNVs

single nucleotide variants

 WES

whole exome sequencing

 References YenPMPhysiological and molecular basis of thyroid hormone actionPhysiol Rev8110971142200110.1152/physrev.2001.81.3.109711427693 ZhangJLazarMAThe mechanism of action of thyroid hormonesAnnu Rev Physiol62439466200010.1146/annurev.physiol.62.1.43910845098 SongYYaoXYingHThyroid hormone action in metabolic regulationProtein Cell2358368201110.1007/s13238-011-1046-x216146724875336 VirginiVBaumgartnerCBischoffTHallerDMFreyPRosemannTColletTHSykiotisGPitteloudNRodondiNComment les médecins de famille prennent-ils en charge l'hypthyroïdie infraclinique?Rev Med Suisse105265292014(In French)24701670 BaumgartnerCBlumMRRodondiNSubclinical hypothyroidism: Summary of evidence in 2014Swiss Med Wkly144w14058201425536449 FuhrerDBrixKBiebermannHUnderstanding the healthy thyroid state in 2015Eur Thyroid J4Suppl 1S1S8201510.1159/000431318 YuHYangYZhangMLuHZhangJWangHCianfloneKThyroid status influence on adiponectin, acylation stimulating protein (ASP) and complement C3 in hyperthyroid and hypothyroid subjectsNutr Metab(Lond)313200610.1186/1743-7075-3-13164723841382235 MillerLDMcPhiePSuzukiHKatoYLiuETChengSYMulti-tissue gene-expression analysis in a mouse model of thyroid hormone resistanceGenome Biol5R31200410.1186/gb-2004-5-5-r3115128445416467 YangNYaoZMiaoLLiuJGaoXXuYWangGHomocysteine diminishes apolipoprotein A-I function and expression in patients with hypothyroidism: A cross-sectional studyLipids Health Dis15123201610.1186/s12944-016-0293-5274577264960745 RobertsCGLadensonPWHypothyroidismLancet363793803200410.1016/S0140-6736(04)15696-115016491 WangYYuXZhaoQZZhengSQingWJMiaoCDSanjayJThyroid dysfunction, either hyper or hypothyroidism, promotes gallstone formation by different mechanismsJ Zhejiang Univ Sci B17515525201610.1631/jzus.B1500210273817284940627 VenezianoLParkinsonMHMantuanoEFrontaliMBhatiaKPGiuntiPA novel de novo mutation of the TITF1/NKX2-1 gene causing ataxia, benign hereditary chorea, hypothyroidism and a pituitary mass in a UK family and review of the literatureCerebellum13588595201410.1007/s12311-014-0570-7249300294155168 Mendieta-ZeronHJimenez-RosalesAPerez-AmadoCJJimenez-MoralesSFOXE1 mutation screening in a case with cleft lip, hypothyroidism, and thyroid carcinoma: A new syndrome?Case Rep Genet201763905452017289289945591984 SunYBakBSchoenmakersNvan TrotsenburgASOostdijkWVosholPCambridgeEWhiteJKle TissierPGharavySNLoss-of-function mutations in IGSF1 cause an X-linked syndrome of central hypothyroidism and testicular enlargementNat Genet4413751381201210.1038/ng.2453231435983511587 WatanabeYSharwoodEGoodwinBCreechMKHassanHYNeteaMGJaegerMDumitrescuARefetoffSHuynhTWeissREA novel mutation in the TG gene (G2322S) causing congenital hypothyroidism in a sudanese family: A case reportBMC Med Genet1969201810.1186/s12881-018-0588-7297201015932782 VincenziMCamilotMFerrariniETeofoliFVenturiGGaudinoRCavarzerePDe MarcoGAgrettiPDimidaAIdentification of a novel pax8 gene sequence variant in four members of the same family: From congenital hypothyroidism with thyroid hypoplasia to mild subclinical hypothyroidismBMC Endocr Disord1469201410.1186/1472-6823-14-69251468934142740 BamshadMJNgSBBighamAWTaborHKEmondMJNickersonDAShendureJExome sequencing as a tool for mendelian disease gene discoveryNat Rev Genet12745755201110.1038/nrg303121946919 NgSBTurnerEHRobertsonPDFlygareSDBighamAWLeeCShafferTWongMBhattacharjeeAEichlerEETargeted capture and massively parallel sequencing of 12 human exomesNature461272276200910.1038/nature08250196845712844771 WangJLYangXXiaKHuZMWengLJinXJiangHZhangPShenLGuoJFTGM6 identified as a novel causative gene of spinocerebellar ataxias using exome sequencingBrain13335103518201010.1093/brain/awq32321106500 LiHDurbinRFast and accurate short read alignment with Burrows-Wheeler transformBioinformatics2517541760200910.1093/bioinformatics/btp324194511682705234 McKennaAHannaMBanksESivachenkoACibulskisKKernytskyAGarimellaKAltshulerDGabrielSDalyMDePristoMAThe genome analysis toolkit: A mapreduce framework for analyzing next-generation DNA sequencing dataGenome Res2012971303201010.1101/gr.107524.110206441992928508 CibulskisKLawrenceMSCarterSLSivachenkoAJaffeDSougnezCGabrielSMeyersonMLanderESGetzGSensitive detection of somatic point mutations in impure and heterogeneous cancer samplesNat Biotechnol31213219201310.1038/nbt.2514233960133833702 WangKLiMHakonarsonHANNOVAR: Functional annotation of genetic variants from high-throughput sequencing dataNucleic Acids Res38e164201010.1093/nar/gkq603206016852938201 IwenKASchroderEBrabantGThyroid hormones and the metabolic syndromeEur Thyroid J28392201310.1159/000351249247830453821514 CangulHAydinBKBasFA homozygous TPO gene duplication (c.1184_1187dup4) causes congenital hypothyroidism in three siblings born to a consanguineous familyJ Pediatr Genet4194198201510.1055/s-0035-1565268276171314906531 OzhanBAnlasBoz OSarikepeBAlbuzBGunduzSemerci NCongenital central hypothyroidism caused by a novel thyroid-stimulating hormone-beta subunit gene mutation in two siblingsJ Clin Res Pediatr Endocrinol9278282201710.4274/jcrpe.4595285150305596811 ParkKJParkHKKimYJLeeKRParkJHParkJHParkHDLeeSYKimJWDUOX2 mutations are frequently associated with congenital hypothyroidism in the korean populationAnn Lab Med36145153201610.3343/alm.2016.36.2.14526709262 DiamantSGorinEShafrirEEnzyme activities related to fatty-acid synthesis in liver and adipose tissue of rats treated with triiodothyronineEur J Biochem26553559197210.1111/j.1432-1033.1972.tb01798.x5025931 OppenheimerJHSchwartzHLLaneJTThompsonMPFunctional relationship of thyroid hormone-induced lipogenesis, lipolysis, and thermogenesis in the ratJ Clin Invest87125132199110.1172/JCI1149611985090295007 YaoXHouSZhangDXiaHWangYCJiangJYinHYingHRegulation of fatty acid composition and lipid storage by thyroid hormone in mouse liverCell Biosci438201410.1186/2045-3701-4-38251050124124172 LudwigUHolznerDDenzerCGreinertAHaenleMMOeztuerkSKoenigWBoehmBOMasonRAKratzerWSubclinical and clinical hypothyroidism and non-alcoholic fatty liver disease: A cross-sectional study of a random population sample aged 18 to 65 yearsBMC Endocr Disord1541201510.1186/s12902-015-0030-5262765514536732 AmarapurkarDKamaniPPatelNGuptePKumarPAgalSBaijalRLalaSChaudharyDDeshpandeAPrevalence of non-alcoholic fatty liver disease: Population based studyAnn Hepatol6161163200717786142 LawKBruntEMNonalcoholic fatty liver diseaseClin Liver Dis14591604201010.1016/j.cld.2010.07.00621055684 Ortiz-LopezCLomonacoROrsakBFinchJChangZKochunovVGHardiesJCusiKPrevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD)Diabetes Care35873878201210.2337/dc11-1849223746403308295 BahtHSSaggersonEDA tissue-specific increase in lipogenesis in rat brown adipose tissue in hypothyroidismBiochem J251553557198810.1042/bj251055330419651149036 RusinekDSwierniakMChmielikEKowalMKowalskaMCyplinskaRCzarnieckaAPiglowskiWKorfantyJChekanMBRAFV600E-associated gene expression profile: Early changes in the transcriptome, based on a transgenic mouse model of papillary thyroid carcinomaPLoS One10e0143688201510.1371/journal.pone.0143688266252604666467 SmithSThe animal fatty acid synthase: One gene, one polypeptide, seven enzymesFASEB J812481259199410.1096/fasebj.8.15.80017378001737 SuburuJShiLWuJWangSSamuelMThomasMJKockNDYangGKridelSChenYQFatty acid synthase is required for mammary gland development and milk production during lactationAm J Physiol Endocrinol Metab306E1132E1143201410.1152/ajpendo.00514.2013246687994116404 BlennemannBLeahyPKimTSFreakeHCTissue-specific regulation of lipogenic mRNAs by thyroid hormoneMol Cell Endocrinol11018199510.1016/0303-7207(95)03509-67672439 YenPMFengXFlamantFChenYWalkerRLWeissREChassandeOSamarutJRefetoffSMeltzerPSEffects of ligand and thyroid hormone receptor isoforms on hepatic gene expression profiles of thyroid hormone receptor knockout miceEMBO Rep4581587200310.1038/sj.embor.embor862127761781319202 BrownMLYuiKSmithJDLeBoeufRCWengWUmedaPKLiRSongRGianturcoSHBradleyWAThe murine macrophage apoB-48 receptor gene (Apob-48r): Homology to the human receptorJ Lipid Res4311811191200212177162 WangKEdmondsonACLiMGaoFQasimANDevaneyJMBurnettMSWaterworthDMMooserVGrantSFPathway-wide association study implicates multiple sterol transport and metabolism genes in HDL cholesterol regulationFront Genet241201110.3389/fgene.2011.00041223033373268595 FujitaYEzuraYBujoHNakajimaTTakahashiKKamimuraKIinoYKatayamaYSaitoYEmiMAssociation of nucleotide variations in the apolipoprotein B48 receptor gene (APOB48R) with hypercholesterolemiaJ Hum Genet50203209200510.1007/s10038-005-0240-115830122 BrownMLRamprasadMPUmedaPKTanakaAKobayashiYWatanabeTShimoyamadaHKuoWLLiRSongRA macrophage receptor for apolipoprotein B48: Cloning, expression, and atherosclerosisProc Natl Acad Sci USA9774887493200010.1073/pnas.12018409710852956

Hypothyroidism pedigree. Exome sequencing was performed on individuals IV:1, III:1, III:2, III:3 and II:3. IV:1 was identified as the proband; I:1 and II:1 were individuals with subclinical hypothyroidism; II:5 was a probable case of hypothyroidism. Circles represent female individuals; squares represent male individuals. W, whole exome sequencing.

(A) Affected amino acid residue was highly conserved between different species. (B) Conserved domains in fatty acid synthase.

(A) Affected amino acid residue was highly conserved between different species. (B) Conserved domains in apolipoprotein B receptor.

Sanger validation results of fatty acid synthase variants in ten family members of the hypothyroidism pedigree. Arrow represents the mutation site.

Sanger validation results of apolipoprotein B receptor variants in ten family members of the hypothyroidism pedigree. Arrow represents the mutation site.

A total of 50 nonsynonymous variants in the pedigree.

Chr Start End Ref Alt Gene.refGene DbSNP138
1 16057042 16057042 G A PLEKHM2 .
1 23238971 23238971 G A EPHB2 .
2 167760021 167760021 A G XIRP2 .
2 169801131 169801131 G A ABCB11 rs118109635
2 172409920 172409920 T C CYBRD1 rs16859487
2 175618404 175618404 C T CHRNA1 .
2 179300979 179300979 A T PRKRA rs77419724
2 179597657 179597657 T G TTN .
2 179632619 179632619 C T TTN rs141258018
2 204304489 204304489 G T RAPH1 rs191393494
2 234869499 234869499 G C TRPM8 .
2 238732983 238732983 G T RBM44 .
3 13670739 13670739 G A FBLN2 rs201340643
3 38087142 38087142 G A DLEC1 rs117463277
3 49701035 49701035 G A BSN rs141950704
3 56597830 56597830 G A CCDC66 rs146224729
4 74363387 74363387 A T AFM rs2276444
6 90578678 90578678 A C CASP8AP2 .
6 168294583 168294583 G A MLLT4 rs150936076
6 170886768 170886768 C G PDCD2 rs140493653
9 140323749 140323749 C T NOXA1 rs201388549
10 86132217 86132217 G T CCSER2 .
11 3249828 3249828 C T MRGPRE rs200334859
11 3681054 3681054 G A ART1 rs2280133
11 3744621 3744621 C T NUP98 rs148384795
11 4411560 4411560 A C TRIM21 .
11 44069816 44069816 G A ACCSL rs182257970
11 58605757 58605757 C T GLYATL2 .
11 62381857 62381857 G A ROM1 .
11 68748268 68748268 A G MRGPRD rs74390416
11 73067275 73067275 C T ARHGEF17 .
11 77838424 77838424 T C ALG8 rs138293432
11 93754643 93754643 T A HEPHL1 rs192979315
13 96242562 96242562 T G DZIP1 .
15 65490592 65490592 C T CILP rs148582730
16 28508245 28508245 C G APOBR rs13306186
16 28948654 28948654 T C CD19 .
17 4076694 4076694 A G ANKFY1 .
17 4856390 4856390 G C ENO3 rs143945974
17 10312678 10312678 A T MYH8 rs151091483
17 19246867 19246867 T C B9D1 rs7221577
17 79167744 79167744 C T CEP131 rs138784674
17 80037439 80037439 C A FASN rs200842352
18 3094191 3094191 C T MYOM1 rs149588924
20 76700 76700 G A DEFB125 rs116934569
20 60575227 60575227 C A TAF4 .
20 60892518 60892518 C T LAMA5 rs200632605
20 61167658 61167658 C G MIR1-1HG rs145416632
21 34951831 34951831 C A DONSON rs190773441
21 40568847 40568847 T C BRWD1 rs73357824

Alt, alteration allele; Chr, chromosome; Ref, reference allele; rs, accession number in single nucleotide polymorphism database Build 138 (https://www.ncbi.nlm.nih.gov/projects/SNP/snp_summary.cgi?view+summary=view+summary&build_id=138).

Sanger sequencing validation results.

Individuals CHRNA1 ABCB11 APOBR FASN TRPM8
Affected sporadic individuals
  1 GG CC CC CC GG
  2 GG CC CC CC GG
  3 GG CC CC CC GG
  4 GG CC CC CC GG
  5 GG CC CC CC GG
  6 GG CC CC CC GG
  7 GG CC CC CC GG
  8 GG CC CC CC GG
  9 GG CC CC CC GG
  10 GG CC CC CC GG
  11 GG CC CC CC GG
  12 GG CC CC CC GG
  13 GG CC CC CC GG
  14 GG CC CC CC GG
  15 GG CC CC CC GG
  16 GG CC CC CC GG
  17 GG CC CC CC GG
  18 GG CC CC CC GG
  19 GG CC CC CC GG
  20 GG CC CC CC GG
Pedigree individuals
  III-2 GG CC CG AC GG
  II-1 GA CT CC CC GC
  II-2 GG CC CC CC GG
  II-1 GG CC CC CC GG
  III-3 GG CC CC CC GG
  III-1 GA CT CC CC GC
  II-5 GA CT CG AC GC
  II-4 GG CC CC CC GG
  II-3 GA CT CG AC GC
  I-1 GG CC CC CC GG
  IV-1 GA CT CG AC GC

ABCB11, ATP binding cassette subfamily B member 11; APOBR, apolipoprotein B receptor; CHRNA1, cholinergic receptor nicotinic α1 subunit; FASN, fatty acid synthase; TRPM8, transient receptor potential cation channel subfamily M member 8.

Clinical information of 20 additional, unrelated individuals with primary hypothyroidism.

Case Sex Age (years) TSH (mU/l) FT4 (pmol/l)
  1 Male 75 27.7 7.31
  2 Male 49 4.85 16.2
  3 Male 47 72 0.88
  4 Male 67 9.15 10.7
  5 Male 47 1.71 15.3
  6 Female 64 3.07 15.7
  7 Female 31 6.21 12.3
  8 Female 21 5.56 11.5
  9 Female 29 1.59 10.3
10 Female 25 5.52 13.2
11 Female 27 4.56 12.7
12 Female 31 3.97 16
13 Female 32 2.57 10
14 Female 68 37 7.08
15 Female 54 5.08 11.5
16 Female 30 57.5 7.16
17 Female 36 4.3 12.2
18 Female 29 0.969 11.4
19 Female 35 9.74 12.4
20 Female 27 4.26 11.5

FT4, free thyroxine; TSH, thyroid-stimulating hormone.